TNF Pharmaceuticals, Inc. ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced that data ...

Relevant professionals include doctors, nurses, dentists, pharmacists, and all allied health and social care professionals. Service managers will also be considered. Frailty is a state of diminished ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented findings from the REPRIEVE trial about the use of statins among people living with HIV with frailty ...

Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data ...

Frailty is increasingly being viewed as an emerging risk factor for poor outcomes among patients with autoimmune or rheumatic diseases. It is also one of the more difficult risk factors to assess, ...

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...

A new study published in JMIR Aging developed and tested a new AI model called HOPE which uses Wi-Fi-based motion sensor data ...

Depression is a common condition that has a significant disease burden on those affected. While medication and psychotherapy are very effective for many patients, they do not work for everyone and can ...

body mass index and frailty. These concepts, which represent interpretable, high-level summaries of the raw data, are the building blocks of human reasoning — the language of clinical debate.

Differences in demographic and clinical characteristics of patients with and without recurrent AMI during 1-year follow-up were examined. To investigate the association between the recurrent AMI and 1 ...

In 2024, the U.S. Food and Drug Administration (FDA) indicated that ELPIS II is a pivotal trial and, if it demonstrates sufficient evidence of efficacy, it would be acceptable for a Biologics License ...

Wa'el Hashad, Chief Executive Officer, Longeveron Inc. MIAMI, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company ...